Nomexor (Nebivolol)

Nebivolol, the active ingredient in Nomexor, is a selective β1‑adrenergic blocker presented as an oral tablet for systemic use. It is indicated for the management of essential hypertension and for reducing morbidity in patients with heart failure with reduced ejection fraction.

GNH USA supplies Nomexor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and regulatory compliance across EU and global markets. Our distribution network adheres to stringent quality standards and provides reliable logistics for timely delivery.

Nebivolol is used to treat cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

- Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure with reduced ejection fraction: improves ventricular performance and decreases mortality. - Left ventricular dysfunction: supports cardiac output and mitigates progression of heart failure.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general weakness. - Bradycardia: slower than normal heart rate. - Nausea or mild gastrointestinal upset. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or sinus arrest. - Marked hypotension leading to fainting. - Atrioventricular block or other cardiac conduction disturbances. - Bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic dysfunction manifested by elevated liver enzymes.

Before initiating Nebivolol therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure adequate control without excessive hypotension. - Heart rate assessment: avoid use in patients with baseline severe bradycardia. - Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction. - Renal or hepatic impairment: dose adjustment may be required. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Verapamil or diltiazem: increased risk of atrioventricular block. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): elevated nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring blood pressure checks. - Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms, necessitating glucose monitoring.